Literature DB >> 19203554

Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.

N Miura1, R Aoyama, W Kitagawa, H Yamada, K Nishikawa, H Imai.   

Abstract

A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment. Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement. Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative. PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively. Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained. One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later. This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203554     DOI: 10.5414/cnp71074

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  ANCA-Associated Vasculitis in Inflammatory Bowel Disease.

Authors:  Jocelyn X Jiang; Karuna Keat; Sanjay Swaminathan
Journal:  Dig Dis Sci       Date:  2019-05-15       Impact factor: 3.199

2.  A limited form of granulomatosis with polyangiitis in an ulcerative colitis patient receiving sulfasalazine.

Authors:  Fahdah Alokaily; Reem AlKathiri; Sarah AlKathiri; Seham Alrashidi
Journal:  Saudi Med J       Date:  2022-01       Impact factor: 1.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.